<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00502632</url>
  </required_header>
  <id_info>
    <org_study_id>1372P</org_study_id>
    <nct_id>NCT00502632</nct_id>
  </id_info>
  <brief_title>Dornase Alfa and Urokinase for Kids With Pleural Empyema</brief_title>
  <acronym>DUKE</acronym>
  <official_title>Multicentre Randomized Double-Blinded Trial of Intrapleural Dornase Alfa and Urokinase vs Urokinase Alone for Complicated Parapneumonic Effusions in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera di Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera di Padova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether intrapleural treatment with Dornase alfa
      plus Urokinase improves clinical outcome compared to Urokinase alone in children with
      complicated parapneumonic effusions
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">October 2009</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of hospital stay</measure>
    <time_frame>From beginning of intrapleural treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Need for additional surgical procedures</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of suction applied to chest drain</measure>
    <time_frame>From beginning of intrapleural treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of fever</measure>
    <time_frame>From beginning of intrapleural treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of intravenous antibiotic treatment</measure>
    <time_frame>From beginning of intrapleural treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Pleural Empyema</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrapleural administration of:
Urokinase 40,000 in 40ml normal saline, twice daily for 4 days
Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intrapleural administration of:
Urokinase 40,000 in 40ml normal saline, twice daily for 4 days
25ml normal saline, twice daily for 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urokinase and Dornase alfa</intervention_name>
    <description>Intrapleural administration of:
Urokinase 40,000 in 40ml normal saline, twice daily for 4 days
Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urokinase</intervention_name>
    <description>Intrapleural administration of:
Urokinase 40,000 in 40ml normal saline, twice daily for 4 days
25ml normal saline, twice daily for 4 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 1 year and &lt; 16 years

          -  Respiratory infection (pneumonia or lung abscess)

          -  Effusion occupying at least 1/3 of hemithorax on chest X-ray

          -  Complicated effusion (presence of at least one of the following):

               -  Hyperechoic pleural fluid on chest US scan

               -  Loculated collection on chest US or CT scan

               -  Purulent pleural fluid

               -  Positive culture or Gram stain on pleural fluid

        Exclusion Criteria:

          -  Non parapneumonic effusion

          -  Immunodeficiency

          -  Neurological impairment

          -  Suspected or proven allergy to Urokinase or Dornase alfa

          -  Suspected or documented bronchopleural fistula

          -  Impaired coagulation (INR&gt;2), haemorrhage, high risk for bleeding

          -  Thoracic surgical procedure (e.g. thoracoscopy, mini-thoracotomy) already performed

          -  Chest drain inserted since 6 or more days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PierGiorgio Gamba, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Ospedaliera di Padova</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giorgio Stefanutti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women's and Children's Hospital, Adelaide, SA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PierGiorgio Gamba, MD</last_name>
    <phone>+39 049 821 3683</phone>
    <email>piergiorgio.gamba@unipd.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maurizio Cheli, MD</last_name>
      <email>mauriziocheli@tin.it</email>
    </contact>
    <investigator>
      <last_name>Maurizio Cheli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PierGiorgio Gamba, MD</last_name>
      <phone>+39 049 821 3683</phone>
      <email>piergiorgio.gamba@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Eleonora Cesca, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonia Viale, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Bambino Gesu'</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Inserra, MD</last_name>
      <phone>+39 06 6859 2423</phone>
      <email>lobina@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Alessandro Inserra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2007</study_first_submitted>
  <study_first_submitted_qc>July 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2007</study_first_posted>
  <last_update_submitted>May 9, 2008</last_update_submitted>
  <last_update_submitted_qc>May 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr PierGiorgio Gamba</name_title>
    <organization>Azienda Ospedaliera di Padova</organization>
  </responsible_party>
  <keyword>Pleural empyema</keyword>
  <keyword>Pleural effusion</keyword>
  <keyword>Dornase alfa</keyword>
  <keyword>Urokinase</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empyema</mesh_term>
    <mesh_term>Empyema, Pleural</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

